Conventional DMARDs rule in psoriatic arthritis treatment

More than half of patients with psoriatic arthritis are being treated with conventional disease-modifying anti-rheumatic drugs alone, despite biological DMARDs having more evidence of efficacy, an Australian study shows.

The cross-sectional study of nearly 3000 patients undergoing treatment for psoriatic arthritis showed 46% were on conventional DMARDs monotherapy and 11% were taking conventional DMARD combinations.

In contrast just 19% were on biologic DMARD monotherapy, 13% were taking combinations of biologic and conventional